Global Medical REIT (GMRE)
(Delayed Data from NYSE)
$9.57 USD
-0.11 (-1.14%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $9.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Global Medical REIT (GMRE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.29 | $11.25 | $9.50 | 6.30% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Global Medical REIT comes to $10.29. The forecasts range from a low of $9.50 to a high of $11.25. The average price target represents an increase of 6.3% from the last closing price of $9.68.
Analyst Price Targets (6 )
Broker Rating
Global Medical REIT currently has an average brokerage recommendation (ABR) of 2.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 28.57% and 14.29% of all recommendations. A month ago, Strong Buy made up 28.57%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/GMRE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/7/2024 | Robert W. Baird & Co. | Wesley Golladay | Hold | Hold |
5/20/2024 | BMO Capital Markets | Juan Sanabria | Hold | Hold |
5/13/2024 | B. Riley Securities | Bryan A Maher | Strong Buy | Strong Buy |
5/9/2024 | Colliers Securities | Barry Oxford | Moderate Buy | Moderate Buy |
3/15/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Hold | Hold |
2/29/2024 | JMP Securities | Aaron Hecht | Hold | Hold |
2/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.29 |
ABR (Last week) | 2.29 |
# of Recs in ABR | 7 |
Average Target Price | $10.29 |
LT Growth Rate | 8.00% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 159 of 252 |
Current Quarter EPS Est: | 0.22 |